Trident Lifeline Limited has filed its H2 & FY26 Earnings Presentation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, dated May 09, 2026. The presentation covers the half-year and full-year ended 31st March, 2026, and was submitted alongside the company's audited standalone and consolidated financial results approved by the Board of Directors on 7th May, 2026. The statutory audit was conducted by M/s A Bafna & Associates, Chartered Accountants, who issued an unmodified opinion on the financial statements prepared in accordance with Indian GAAP.

Company Overview

Trident Lifeline is a rapidly growing pharmaceutical company engaged in manufacturing pharmaceutical formulations under its own brands and facilities, as well as through loan license and contract manufacturing models. The company operates a hybrid manufacturing model and has a presence in African, Latin American, CIS, and East Asian countries, spanning 46 countries globally. As on March 31, 2026, the company had 1,091 export market products registered and 2,534 export market product registrations in process, with a total of 3,625 product registration applications filed to date. Venezuela, Ghana, Cambodia, and Kenya combined account for approximately 60% of total products registered and under registration. The company has over 61 brands with registered trademarks.

Trident Lifeline's subsidiary structure includes TNS Pharma Private Limited (51% stake), TLL Wellness Limited (51% stake), TLL Elements Private Limited (100% wholly owned subsidiary), a 6.21% stake in TLL Industries (formerly Tricorp Industries Limited), TLL Parenterals (51% stake acquired on 2nd December 2024), and Trident Mediquip Limited (59.77% stake as on 31st March, 2026).

H2FY26 Financial Performance

Trident Lifeline delivered strong performance in H2FY26, with revenue growing 47% year-on-year driven by expansion across domestic and export markets. EBITDA margins remained stable at 27%, and PAT for H2FY26 reached an all-time high. The following table summarises the standalone H2FY26 profit and loss snapshot:

Standalone Financial Performance

For FY26, Trident Lifeline crossed ₹100 crore in Revenue from Operations for the first time. Net sales/income from operations increased to INR 10,189.95 lacs from INR 6,779.91 lacs in the previous year. Total income, including other income of INR 417.09 lacs, stood at INR 10,607.05 lacs compared to INR 7,094.00 lacs in FY25. Net profit for the year grew to INR 1,809.27 lacs from INR 1,305.13 lacs. The multi-year standalone profit and loss trend is presented below:

Paid-up equity share capital as at 31st March, 2026 was INR 1,193.30 lacs (face value INR 10/- each). Basic and diluted EPS (not annualised) for FY26 stood at 15.50.

Consolidated Financial Performance

On a consolidated basis, the group reported total income of INR 13,829.28 lacs for FY26, compared to INR 9,519.58 lacs in FY25. Net profit after minority interest for the year stood at INR 1,904.14 lacs, up from INR 1,174.79 lacs in the previous year. Consolidated total assets grew to INR 23,682.90 lacs as at 31st March, 2026 from INR 15,600.50 lacs as at 31st March, 2025.

Balance Sheet and Cash Flow

The standalone balance sheet as at 31st March, 2026 reflects total assets of INR 15,919.06 lacs, up from INR 9,779.20 lacs in the previous year. Reserves & Surplus increased to INR 8,342.52 lacs from INR 5,422.72 lacs. The multi-year standalone balance sheet snapshot is as follows:

On a standalone basis, net cash flow from operating activities was INR 793.22 lacs, while net cash used in investing activities was INR (2,007.36) lacs. The closing standalone cash balance was INR 406.64 lacs. On a consolidated basis, net cash flow from operating activities was INR 469.07 lacs, and net cash used in investing activities stood at INR (3,661.08) lacs, with a closing consolidated cash balance of INR 422.22 lacs. The multi-year standalone cash flow snapshot is presented below:

Product Portfolio and Revenue Mix

The company's product portfolio spans multiple therapeutic categories including Anti Bacterial, Anti Malarial, Anti Diabetic, Anti Fungal, Proton Pump Inhibitors, Nutraceuticals, and NSAIDs, among others. Product forms include tablets, capsules, syrups, suspensions, creams, gels, mouthwash, and toothpaste. Tablets are the largest product category, accounting for 67% of revenue, followed by capsules at 30%. Syrups, suspensions, and toothpaste/mouthwash/other ointments each contribute 1% to revenue. The company is an export-oriented business with Asia as a major export market, followed by an increasing share in Africa.

Strategy and Compliance

Trident Lifeline's strategic priorities include adding 300–400 additional product registrations each year, growing the product portfolio with at least 50–100 registrations in each key market, expanding its dedicated sales and marketing team, and appointing country and geographical sales heads for key markets. The company also focuses on molecules going off-patent in developed markets as a growth opportunity. The company reported nil investor complaints pending at the beginning, during, and at the end of the year. The Board also appointed DAC & Co., Chartered Accountants, as Internal Auditor for the Financial Year 2026-27. The company is listed on the SME Platform of BSE.

Trident Lifeline Limited has announced a board meeting scheduled for Tuesday, May 5, 2026, to review and approve crucial financial results for the fiscal year 2026. The company has formally notified BSE Limited about this important corporate development in accordance with regulatory requirements.

Board Meeting Agenda

The board meeting will address several key items as outlined in the company's official communication:

Regulatory Compliance

The meeting notification has been issued pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates listed companies to provide advance notice of board meetings where financial results will be considered.

Trading Window Restrictions

In compliance with insider trading prevention measures, Trident Lifeline Limited has implemented specific trading restrictions:

• Closure Date: Trading window closed from April 1, 2026
• Reopening: 48 hours after results are made public on May 5, 2026
• Regulatory Basis: SEBI (Prohibition of Insider Trading) Regulations, 2015
• Internal Framework: Company's Code of Conduct

The trading window closure was communicated through the company's letter dated March 31, 2026, ensuring all stakeholders were adequately informed about the restrictions.

Company Information

Traident Lifeline Limited, formerly known as Trident Lifeline Private Limited, operates under CIN L51909GJ2014PLC078227. The company is listed on BSE with Stock ID TLL and maintains its registered office in Surat, Gujarat. The notification was signed by Company Secretary and Compliance Officer Nikita Sharma on April 29, 2026.